European Journal of Cancer
Volume 41, Issue 17 , Pages 2690-2700 , November 2005

Preventing organ-specific chemotherapy toxicity

Received 12 April 2005 ,Accepted 18 May 2005.

References 

  1. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991;266(12):1672–1677
  2. Larsen R, Jakacki R, Vetter V, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol. 1992;70:73–77
  3. Silber JH, Jakacki RI, Larsen RL, et al. Increased risk of cardiac dysfunction after anthracyclines in girls. Med Pediatr Oncol. 1993;21(7):477–479
  4. Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19(1):191–196
  5. Silber JH, Kaizer H. Marginal analysis applied to the dose-response curve. Med Pediatr Oncol. 1988;16(5):344–348
  6. Sorensen K, Levitt G, Bull C, et al. Anthracycline dose in childhood acute lymphoblastic leukaemia: issues of early survival versus late cardiotoxicity. J Clin Oncol. 1997;15(1):61–68
  7. Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982;96(2):133–139
  8. Shapira J, Gotfried M, Lishner M, et al. Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomised evaluation. Cancer. 1990;65(4):870–873
  9. Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer. 1991;68(6):1221–1229
  10. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 acute lymphoblastic leukaemia protocol. J Clin Oncol. 2002;20(6):1677–1682
  11. Samuel L, Cummings J, Shaw P. Daunorubicin cardiotoxicity in childhood cancer. Lancet. 1998;352(9134):1150
  12. Bielack SS, Erttmann R, Winkler K, et al. Doxorubicin: effect of different schedules on toxicity and anti-tumour efficacy. Eur J Cancer Clin Oncol. 1989;25(5):873–882
  13. Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500mg/m2. Ann Oncol. 2000;11(8):1029–1033
  14. Lyass O, Uziely B, Ben-Yosef R, et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer. 2000;89(5):1037–1047
  15. Northfelt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma: results of a randomised phase III clinical trial. J Clin Oncol. 1998;16(7):2445–2451
  16. Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumours: a paediatric oncology group study. Clin Cancer Res. 2002;8(2):413–418
  17. Torti FM, Bristow MM, Lum BL, et al. Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res. 1986;46(7):3722–3727
  18. Wexler LH, Andrich MP, Venzon D, et al. Randomised trial of the cardioprotective agent ICRF-187 in paediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14(2):362–372
  19. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukaemia. N Engl J Med. 2004;351(2):145–153
  20. Winter SC, Buist NR. Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. Am Heart J. 2000;139(2 Pt 3):S63–S69
  21. Iliceto S, Scrutinio D, Bruzzi P, et al. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial. J Am Coll Cardiol. 1995;26(2):380–387
  22. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. Am Heart J. 2000;139(2 Pt 3):S120–S123
  23. Zales VR, Benson DW. Reversible cardiomyopathy due to carnitine deficiency from renal tubular wasting. Pediatr Cardiol. 1995;16(2):76–78
  24. Strohm G, Payne C, Alberts D, et al. Cardiotoxic effects of doxorubicin with and without carnitine: usefulness of the mouse model in assessment. Arch Path Lab Med. 1982;106(4):181–185
  25. Abdel-aleem S, Karim AM, Zarouk WA, et al. Reduced effects of L-carnitine on glucose and fatty acid metabolism in myocytes isolated from diabetic rats. Horm Metab Res. 1997;29(9):430–435
  26. Sayed-Ahmed MM, Shaarawy S, Shouman SA, et al. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol Res. 1999;39(4):289–295
  27. Yoon HR, Hong YM, Boriack RL, et al. Effect of L-carnitine supplementation on cardiac carnitine palmitoyltransferase activities and plasma carnitine concentrations in adriamycin-treated rats. Pediatr Res. 2003;53(5):788–792
  28. Hauser M, Gibson BS, Wilson N. Diagnosis of anthracycline-induced late cardiomyopathy by exercise-spiroergometry and stress-echocardiography. Eur J Pediatr. 2001;160(10):607–610
  29. Silber JH. Role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatr Blood Cancer. 2005;44(7):607–613
  30. Lipshultz SE, Colan SD. Cardiovascular trials in long-term survivors of childhood cancer. J Clin Oncol. 2004;22(5):769–773
  31. Silber JH, Cnaan A, Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of paediatric cancer exposed to anthracyclines. J Clin Oncol. 2004;22:
  32. Womer RB, Pritchard J, Barratt TM. Renal toxicity of cisplatin in children. J Pediatr. 1985;106(4):659–663
  33. Erdlenbruch B, Nier M, Kern W, et al. Pharmacokinetics of cisplatin and relation to nephrotoxicity in paediatric patients. Eur J Clin Pharmacol. 2001;57(5):393–402
  34. Petrilli AS, Oliveira DT, Ginani VC, et al. Use of amifostine in the therapy of osteosarcoma in children and adolescents. J Pediatr Hematol Oncol. 2002;24(3):188–191
  35. Chang B, Nishikawa M, Sato E, et al. L-Carnitine inhibits cisplatin-induced injury of the kidney and small intestine. Arch Biochem Biophys. 2002;405(1):55–64
  36. Doolittle ND, Muldoon LL, Brummett RE, et al. Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumours. Clin Cancer Res. 2001;7(3):493–500
  37. Skinner R. Chronic ifosfamide nephrotoxicity in children. Med Pediatr Oncol. 2003;41(3):190–197
  38. Skinner R, Sharkey IM, Pearson AD, et al. Ifosfamide, mesna, and nephrotoxicity in children. J Clin Oncol. 1993;11(1):173–190
  39. Raney B, Ensign LG, Foreman J, et al. Renal toxicity of ifosfamide in pilot regimens of the intergroup rhabdomyosarcoma study for patients with gross residual tumour. Am J Pediatr Hematol Oncol. 1994;16(4):286–295
  40. Zaki E, Springate J, Taub M. Comparative toxicity of ifosfamide metabolites and protective effect of mesna and amifostine in cultured renal tubule cells. Toxicol In Vitro. 2003;17(4):397–402
  41. de Kraker J, Bierings M, Offringa M. Lack of protection of proximal tubular cells by amifostine (ethyol) in ifosfamide-containing regimens. Med Pediatr Oncol. 2000;34(1):78–79
  42. Aisenberg J, Hsieh K, Kalaitzoglou G, et al. Bone mineral density (BMD) in long-term survivors of childhood cancer. J Pediatr Hematol Oncol. 1998;20:241–245
  43. Arikoski P, Komulainen J, Riikonen P, et al. Reduced bone density at completion of chemotherapy for a malignancy. Arch Dis Child. 1999;80(2):143–148
  44. Brennan BM, Rahim A, Adams JA, et al. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer. 1999;79(11–12):1859–1863
  45. Bhatia S, Ramsay NK, Weisdorf D, et al. Bone mineral density in patients undergoing bone marrow transplantation for myeloid malignancies. Bone Marrow Transplant. 1998;22(1):87–90
  46. Brennan B, Shalet SM. Reduced bone mineral density at completion of chemotherapy for a malignancy. Arch Dis Child. 1999;81(4):372
  47. Ecklund K, Laor T, Goorin AM, et al. Methotrexate osteopathy in patients with osteosarcoma. Radiology. 1997;202(2):543–547
  48. van der Sluis IM, van den Heuvel-Eibrink MM, Hahlen K, et al. Bone mineral density, body composition, and height in long-term survivors of acute lymphoblastic leukaemia in childhood. Med Pediatr Oncol. 2000;35(4):415–420
  49. Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337(10):670–676
  50. Srivastava T, Alon US. Bisphosphonates: from grandparents to grandchildren. Clin Pediatr (Phila). 1999;38(12):687–702
  51. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced osteoporosis intervention study group. N Engl J Med. 1998;339(5):292–299
  52. Barr RD, Guo CY, Wiernikowski J, et al. Osteopenia in children with acute lymphoblastic leukaemia: a pilot study of amelioration with Pamidronate. Med Pediatr Oncol. 2002;39(1):44–46
  53. Mattano LA, Sather HN, Trigg ME, et al. Osteonecrosis as a complication of treating acute lymphoblastic leukaemia in children: a report from the Children’s Cancer Group. J Clin Oncol. 2000;18(18):3262–3272
  54. Strauss AJ, Su JT, Dalton VM, et al. Bony morbidity in children treated for acute lymphoblastic leukaemia. J Clin Oncol. 2001;19(12):3066–3072
  55. Wei SY, Esmail AN, Bunin N, et al. Avascular necrosis in children with acute lymphoblastic leukaemia. J Pediatr Orthop. 2000;20(3):331–335
  56. Miyanishi K, Yamamoto T, Irisa T, et al. A high low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio as a potential risk factor for corticosteroid-induced osteonecrosis in rabbits. Rheumatology (Oxford). 2001;40(2):196–201
  57. Jones JP. Fat embolism and osteonecrosis. Orthop Clin North Am. 1985;16(4):595–633
  58. Wang GJ, Chung KC, Shen WJ. Lipid clearing agents in steroid-induced osteoporosis. J Formos Med Assoc. 1995;94(10):589–592
  59. Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid-induced osteonecrosis. Clin Orthop. 2000;370:295–310
  60. Cui Q, Wang GJ, Su CC, et al. The Otto Aufranc Award. Lovastatin prevents steroid induced adipogenesis and osteonecrosis. Clin Orthop. 1997;344:8–19
  61. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop. 2001;386:173–178
  62. Astrand J, Aspenberg P. Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats. BMC Musculoskelet Disord. 2002;3(1):19
  63. Agarwala S, Sule A, Pai BU, et al. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford). 2002;41(3):346–347
  64. Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol. 1996;27(2):74–78
  65. Heikens J, Behrendt H, Adriaanse R, et al. Irreversible gonadal damage in male survivors of paediatric Hodgkin’s disease. Cancer. 1996;78(9):2020–2024
  66. Papadakis V, Vlachopapadopoulou E, Van Syckle K, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol. 1999;32(5):366–372
  67. Charak BS, Gupta R, Mandrekar P, et al. Testicular dysfunction after cyclophosphamide-vincristine-procarbazine-prednisolone chemotherapy for advanced Hodgkin’s disease. A long-term follow-up study. Cancer. 1990;65(9):1903–1906
  68. Hassel JU, Bramswig JH, Schlegel W, et al. Testicular function after OPA/COMP chemotherapy without procarbazine in boys with Hodgkin’s disease. Results in 25 patients of the DAL-HD-85 study. Klin Padiatr. 1991;203:268–272
  69. Kulkarni SS, Sastry PS, Saikia TK, et al. Gonadal function following ABVD therapy for Hodgkin’s disease. Am J Clin Oncol. 1997;20(4):354–357
  70. Viviani S, Santoro A, Ragni G, et al. Gonadal toxicity after combination chemotherapy for Hodgkin’s disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol. 1985;21(5):601–605
  71. Muller J, Sonksen J, Sommer P, et al. Cryopreservation of semen from pubertal boys with cancer. Med Ped Oncol. 2000;34:191–194
  72. Palermo GD, Cohen J, Alikani M, et al. Intracytoplasmic sperm injection: a novel treatment for all forms of male factor infertility. Fertil Steril. 1995;63:1231–1240
  73. Pfeifer SM, Coutifaris C. Reproductive technologies 1998: options available for the cancer patient. Med and Ped Oncol. 1999;33:34–40
  74. Chan PTK, Palermo GD, Veeck LL, et al. Testicular sperm extraction combined with intracytoplasmic sperm injection in the treatment of men with persistent azoospermia postchemotherapy. Cancer. 2001;92:1632–1637
  75. Damani MN, Masters V, Meng MV, et al. Postchemotherapy ejaculatory azoospermia: fatherhood with sperm from testis tissue with intracytoplasmic sperm injection. J Clin Oncol. 2002;20:930–936
  76. Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys. 1990;19:873–880
  77. Johnson DH, Linde R, Hainsworth JD, et al. Effect of luteinizing hormone releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood. 1985;65:832–836
  78. Waxman JH, Ahmed R, Smith D, et al. Failure to preserve fertility in patients with Hodgkin’s disease. Cancer Chemother Pharmacol. 1987;19:159–162
  79. Constine LS. Late effects of radiation therapy. Paediatrician. 1991;18(1):37–48
  80. Nicosia SV, Matus-Ridley M, Meadows AT. Gonadal effects of cancer therapy in girls. Cancer. 1985;55(10):2364–2372
  81. Damewood M, Grochow L. Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil Steril. 1986;45:443–459
  82. Mayer EI, Dopfer RE, Klingebiel T, et al. Longitudinal gonadal function after bone marrow transplantation for acute lymphoblastic leukaemia during childhood. Pediatr Transplant. 1999;3(1):38–44
  83. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin’s disease with assessment of gonadal and cardiac toxicity. J Clin Oncol. 1995;13(2):387–395
  84. Thomson AB, Critchley HO, Wallace WH. Fertility and progeny. Eur J Cancer. 2002;38(12):1634–1644discussion 1645-6
  85. Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG. 2002;109(2):107–114
  86. Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med. 1987;19:1315–1321
  87. Santoro A, Valagussa P. Advances in the treatment of Hodgkin’s disease. Curr Opin Oncol. 1992;4(5):821–828
  88. Thomson AB, Critchley HO, Kelnar CJ, et al. Late reproductive sequelae following treatment of childhood cancer and options for fertility preservation. Best Pract Res Clin Endocrinol Metab. 2002;16(2):311–334
  89. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotrophin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod. 1996;11(8):1620–1626
  90. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol. 2002;187:93–105
  91. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma. 1999;33(1–2):65–76
  92. Bahadur G, Steele SJ. Ovarian tissue cryopreservation for patients. Hum Reprod. 1996;11(10):2215–2216
  93. Donnez J, Godin PA, Qu J, et al. Gonadal cryopreservation in the young patient with gynaecological malignancy. Curr Opin Obstet Gynecol. 2000;12(1):1–9
  94. Newton H. The cryopreservation of ovarian tissue as a strategy for preserving the fertility of cancer patients. Hum Reprod Update. 1998;4(3):237–247
  95. Friedman DL. The ovary. In:  Schwartz CL,  Hobbie WL,  Constine LS, et al. editor. Survivors of childhood cancer: assessment and management. 2nd ed.. Springer-Verlag; 2005;p. 203–212
  96. Oktay K, Buyuk E, Veeck L, et al. Embryo development after heterotopic transplantation of cryopreserved ovarian tissue. Lancet. 2004;363(9412):837–840
  97. Ries L, Smith M, Gurney J, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. Bethesda: National Cancer Institute SEER Program; 1999;
  98. Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am. 2002;49(5):1083–1106

PII: S0959-8049(05)00722-7

doi: 10.1016/j.ejca.2005.05.016

European Journal of Cancer
Volume 41, Issue 17 , Pages 2690-2700 , November 2005

Article Tools